Studies in progress will determine the effect of longer durations of treatment with the peptide, mechanisms of resistance and combinations of the peptide with agents used to treat prostate cancer, that include taxotere and DNA damaging agents, given the role of E2F-1 in DNA repair [5]. This evidence concerns the gene E2F1 and Familial prostate cancer.